KinergyCare is a Virginia-based startup and a Virginia Bio member that is requesting feedback from this community on a care coaching and coordination approach that focuses on the needs of patients with cardiovascular disease. We’re pioneering a new approach that combines patient data on health capabilities with a personalized intervention based on behavioral science. The result should be a more personalized clinical intervention and coaching approach that better ensures lasting behavioral change. We’re looking to talk with stakeholders such as cardiologists, nurses, care management teams, and administrators to learn more about the unmet needs. This outreach is part of our participation in the Spring cohort of the Roanoke Acceleration and Mentoring Program (RAMP), so we would really appreciate any help. Please help us by filling in this brief, 10 question survey. Also, if you have some guidance or can connect us with someone in your network that fits the above roles please contact KinergyCare CEO Art Spivy at aspivy@kinergycare.com or (571) 277-5373. Thanks for your help!
News
Recent News
05/08/2026
RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System
RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital …
05/06/2026
RoVa Labs Opens as Transformational Investment in Roanoke Region’s Innovation Economy
Leaders from Carilion Clinic, the City of Roanoke, Roanoke Blacksburg Innovation Alliance (RBIA), and Virginia Western Community College cut the ribbon on years of hard work with the opening of RoVa Labs, a 40,000-square-foot biotech incubator designed to accelerate commercialization, strengthen the Roanoke Innovation Corridor, and position the region as an emerging destination for life …
05/04/2026
ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD PPI-Partial Responder Patients at DDW 2026
ISOThrive Inc. announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to proton pump inhibitors (PPIs), demonstrating statistically significant and clinically meaningful reductions in heartburn incidence, severity, and regurgitation. The company’s Chief Medical Officer is presenting these results at Digestive Disease Week (DDW) 2026 this week. NERD represents approximately 70% of …